Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 4/20 | 0.43 |
| ▸ | KMT5A | Q9NQR1 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8253901 | 0.90 | USP2 (0.51) | USP2SMN1; SMN2TLR8CHRM2CHRM1 | |
| SCHEMBL6486601 | 0.90 | MEN1 (0.45) | USP2SMN1; SMN2TLR8CHRM2CHRM1 | |
| SCHEMBL311100 | 0.89 | CHRM2 (0.50) | USP2SMN1; SMN2TLR8CHRM2CHRM1 | |
| SCHEMBL20873847 | 0.89 | USP2 (0.53) | USP2SMN1; SMN2TLR8CHRM2CHRM1 | |
| SCHEMBL943825 | 0.88 | TLR8 (0.47) | USP2SMN1; SMN2TLR8CHRM2CHRM1 | |
| SCHEMBL18751236 | 0.86 | TLR8 (0.47) | USP2SMN1; SMN2TLR8CHRM2CHRM1 | |
| SCHEMBL12264373 | 0.86 | TLR8 (0.47) | USP2SMN1; SMN2TLR8CHRM2CHRM1 | |
| SCHEMBL29263655 | 0.86 | TLR8 (0.47) | USP2SMN1; SMN2TLR8CHRM2CHRM1 | |
| SCHEMBL12193455 | 0.86 | USP2 (0.47) | USP2SMN1; SMN2TLR8CHRM2CHRM1 | |
| SCHEMBL8526096 | 0.86 | TLR8 (0.54) | USP2SMN1; SMN2TLR8CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962911-B2 | Pyrrolopyrimidinone derivatives, process of preparation and use | SK CHEMICALS CO., LTD. (KR) | 2005-11-08 | — | — | US | disclosed |
| EP-1257553-B1 | PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE | SK CHEMICALS CO LTD (KR) | 2004-05-26 | — | — | EP | disclosed |
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | SK CHEMICALS CO., LTD. (KR) | 2003-09-11 | — | — | US | disclosed |
| EP-1257553-A1 | PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE | SK Chemicals Co., Ltd. (KR) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001060825-A1 | PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE | SK CHEMICALS CO., LTD. (KR) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | CYP2C19, DHPS, SDHA | USP2 4227/4885SMN1; SMN2 2323/4885TLR8 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.